Cantabio Pharmaceuticals Inc. announced that Dr. Gergely Toth, Cantabio's CEO, will present results of the company's Tau protein targeting small molecule pharmacological chaperone therapeutic program at the 13thInternational Conference on Alzheimer's and Parkinson's Disease held in Vienna between March 29 - April 2. Aggregation of the Tau protein is linked to the onset and progression of Alzheimer's disease (AD) and other Tauopathies, a subset of neurodegenerative disorders, including AD and frontotemporal dementias. Tau is one of the most recognized targets for the potential treatment of AD. The presentations will describe the positive biological activity in cellular and in vivo models of AD of Cantabio's novel Tau protein targeting small molecule drug candidates including: Significant alleviation of movement deficit in a genetically modified, human Tau over-expressing fly in its motor neurons, an in vivo disease AD model and Significant reduction of the formation of Tau aggregates in vitro and in Tau over-expressing N2a neublastoma cells.